| 名稱 | Degrasyn |
| 描述 | Degrasyn (WP1130) (WP1130), a specific deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor, also inhibits Bcr/Abl, which is a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT). |
| 細胞實驗 | Cells are treated with increasing concentrations of WP1130 (0.08-10 μM) in 96-well plates. Plates are incubated at 37 °C for 72 hours, after which 20 μL of MTT reagent is added, and the plates are incubated at 37 °C for another 2 hours. Cells are lysed with 100 μL lysis buffer (20% sodium dodecyl sulfate [SDS] in 50% N, N-dimethylformamide adjusted to pH 4.7 with 80% acetic acid and 1 M hydrochloric acid; final concentration of acetic acid is 2.5% and hydrochloric acid is 2.5%) and incubated for 6 hours. The optical density of each sample at 570 nm is determined with a SPECTRA MAX M2 plate reader.(Only for Reference) |
| 激酶實驗 | To determine binding kinetic constants, liver or kidney plasma membranes are incubated with increasing concentrations of [3H]-AVP with or without excess (1 μM) unlabelled AVP to obtain a saturation curve. To investigate whether mozavaptan interacts competitively or noncompetitively, the saturation binding of [3H]-AVP is examined in the absence and presence of mozavaptan at concentrations of 0.3 μM and 1 μM in liver membranes and 3 nM, and 10 nM in kidney membranes. Data on the saturation curve are plotted according to the method of Scatchard and fitted by a regression analysis[1]. |
| 體外活性 | 除了快速下調Bcr/Abl而不影響B(tài)cr或c-Abl之外，WP1130還調節(jié)Jak2和c-Myc的穩(wěn)定性，但不影響其他激酶（HER1, HER2, c-Kit, FAK, ERK1, ERK2, Akt, Btk, Src及Src相關激酶）或轉錄因子（野生型p53, STAT1, STAT3, STAT5, c-Jun, NF-κB及Max）。與adaphostin和Trisenox不同，WP1130在60分鐘內就能引起B(yǎng)cr/Abl的下調。WP1130誘導髓系和淋巴系腫瘤細胞凋亡的效率更高，IC50約為0.5-2.5 μM。與之相比，對正常CD34+造血前體細胞、皮膚成纖維細胞或內皮細胞的IC50約為5-10 μM。WP1130（5 μM）特異性和快速地下調野生型及T315I突變型Bcr/Abl蛋白，而不影響bcr/abl基因表達或介入蛋白酶體降解途徑，在慢性髓性白血病（CML）細胞中伴隨著凋亡的誘導。WP1130在減少白血病細胞集落形成方面比對正常祖細胞更為有效，并且能有效針對攜帶T315I突變的原發(fā)性白血病細胞。WP1130誘導MM-1多發(fā)性骨髓瘤和其他腫瘤細胞系中c-Myc蛋白的快速蛋白酶體依賴性降解，與腫瘤生長抑制相關。與AG490不同，WP1130作為部分選擇性脫泛素化酶（DUB）抑制劑，能引起快速而顯著的polyubiquitinated (K48/K63-linked)蛋白質積累于近核聚集體，而不影響蛋白酶體活性。WP1130（5 μM）直接抑制USP9x, USP5, USP14, UCH-L1及UCH37的DUB活性，但不影響UCH-L3，導致抗凋亡蛋白下調及促凋亡蛋白上調，如MCL-1和p53。 |
| 體內活性 | WP1130的施用抑制了裸鼠體內移植的K562腫瘤以及野生型Bcr/Abl和T315I突變型Bcr/Abl表達的BaF/3細胞的生長。[1] 與c-Myc的下調一致，WP1130在裸鼠體內建立的A375黑色素瘤腫瘤中展示了強大的抑制活性。[2] |
| 存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | Ethanol : 15 mg/mL (39 mM)
H2O : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 45 mg/mL (117.11 mM), Sonication is recommended.
|
| 關鍵字 | Autophagy | Inhibitor | DUBs | inhibit | Degrasyn | WP-1130 | Deubiquitinase | Apoptosis | WP 1130 | Bcr-Abl |
| 相關產品 | Guanidine hydrochloride | Naringin | Valproic Acid | L-Glutamic acid | Gefitinib | Hydroxychloroquine | Dextran sulfate sodium salt (MW 4500-5500) | Stavudine | Tributyrin | L-Ascorbic acid | Paeonol | Sodium 4-phenylbutyrate |
| 相關庫 | 抑制劑庫 | 抗癌活性化合物庫 | 經典已知活性庫 | 已知活性化合物庫 | 細胞周期化合物庫 | 激酶抑制劑庫 | 抗衰老化合物庫 | 泛素化化合物庫 | 神經退行性疾病化合物庫 | 酪氨酸激酶分子庫 |